[go: up one dir, main page]

AR128330A1 - Inductores químicos de degradación conjugados con anticuerpo y métodos de estos - Google Patents

Inductores químicos de degradación conjugados con anticuerpo y métodos de estos

Info

Publication number
AR128330A1
AR128330A1 ARP230100152A ARP230100152A AR128330A1 AR 128330 A1 AR128330 A1 AR 128330A1 AR P230100152 A ARP230100152 A AR P230100152A AR P230100152 A ARP230100152 A AR P230100152A AR 128330 A1 AR128330 A1 AR 128330A1
Authority
AR
Argentina
Prior art keywords
alkyl
hydrogen
formula
remainder
group
Prior art date
Application number
ARP230100152A
Other languages
English (en)
Inventor
Daniel P Sutherlin
Donglu Zhang
Summer A Baker-Dockrey
Peter S Dragovich
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of AR128330A1 publication Critical patent/AR128330A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

El objeto descrito en la presente se refiere en general a moléculas que contienen maleimida hidrolizables que son útiles como ligadores para unir covalentemente inductores químicos de degradación con anticuerpos y con los conjugados producidos con estos, y sus usos para tratar afecciones, y a los usos de los conjugados en el tratamiento de enfermedades y afecciones donde la degradación de la proteína diana es beneficiosa. Reivindicación 1: Un compuesto que tiene la estructura: L¹-D en donde, D es un CIDE; L¹ es un ligador-1 unido covalentemente a D y que tiene una estructura de fórmula (1), en donde, Z es -(CH₂)ₚ- o -CH₂-(CH₂-O-CH₂)ₚ-CH₂-; p es un número entero de 1 a 24; RA es hidrógeno, alquil C₁₋₆ o -(CH₂)ᵛ-arilo, en donde v es 0 o 1; Q se selecciona del grupo que consiste en: i) un resto de fórmula (2), en donde q es 1, 2, 3 o 4; y ii) un resto de fórmula (3), en donde t es 0, 1, 2, 3 o 4; Q¹ es hidrógeno, un resto de fórmula (4) o de fórmula (5), en donde R² es hidrógeno, haloalquil C₁₋₆ o alquil C₁₋₆; y L¹⁻A es: un compuesto de fórmula (6), en donde el resto de fórmula (7) indica el punto de unión a D; w es 0, 1, 2, 3, 4 o 5; J se selecciona del grupo que consiste en alquil C₁₋₅, -N(Rˣ)(Rʸ), -C(O)NH₂, -NH-C(O)-NH₂ y -NH-C(NH)-NH₂, en donde cada uno de Rˣ y Rʸ se selecciona independientemente de hidrógeno y alquil C₁₋₃; K se selecciona del grupo que consiste en alquilen C₁₋₃, -CH(R)-, -C(O)-, -C(O)-O-CH(R)-, -CH₂-O-C(O)-, -CH₂-O-C(O)-NH-CH₂- y -CH₂-O-C(O)-R-[CH₂]ᵘ-O-, en donde R es hidrógeno, alquil C₁₋₃, N(Rˣ)(Rʸ), -O-N(Rˣ)(Rʸ) o C(O)-N(Rˣ)(Rʸ), en donde u es 0, 1, 2 o 3, y en donde cada uno de Rˣ y Rʸ se selecciona independientemente de hidrógeno y alquil C₁₋₃, o Rˣ y Rʸ, junto con el nitrógeno al que está unido cada uno, forman un heterociclilo de 5 a 7 miembros opcionalmente sustituido; cada uno de RC y RD se selecciona independientemente de hidrógeno y alquil C₁₋₃, o RC y RD, junto al carbono al que está unido cada uno, forman un cicloalquil C₃₋₆ opcionalmente sustituido; y cada uno de R⁷ y R⁸ es independientemente hidrógeno, halo, alquil C₁₋₅, alcoxi C₁₋₅ o hidroxilo.
ARP230100152A 2022-01-26 2023-01-24 Inductores químicos de degradación conjugados con anticuerpo y métodos de estos AR128330A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202263303447P 2022-01-26 2022-01-26

Publications (1)

Publication Number Publication Date
AR128330A1 true AR128330A1 (es) 2024-04-17

Family

ID=85477901

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP230100152A AR128330A1 (es) 2022-01-26 2023-01-24 Inductores químicos de degradación conjugados con anticuerpo y métodos de estos

Country Status (7)

Country Link
US (1) US20250064968A1 (es)
EP (1) EP4469090A1 (es)
JP (1) JP2025506357A (es)
CN (1) CN118591393A (es)
AR (1) AR128330A1 (es)
TW (1) TW202340146A (es)
WO (1) WO2023147328A1 (es)

Family Cites Families (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
AU634186B2 (en) 1988-11-11 1993-02-18 Medical Research Council Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5091542A (en) * 1990-03-09 1992-02-25 Hybritech Incorporated Tris-maleimido compounds as intermediates in trifunctional antibody synthesis
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
US5587458A (en) 1991-10-07 1996-12-24 Aronex Pharmaceuticals, Inc. Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
EP1997894B1 (en) 1992-02-06 2011-03-30 Novartis Vaccines and Diagnostics, Inc. Biosynthetic binding protein for cancer marker
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US20030185830A1 (en) 1997-02-25 2003-10-02 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US7033827B2 (en) 1997-02-25 2006-04-25 Corixa Corporation Prostate-specific polynucleotide compositions
US6319688B1 (en) 1997-04-28 2001-11-20 Smithkline Beecham Corporation Polynucleotide encoding human sodium dependent phosphate transporter (IPT-1)
US20030060612A1 (en) 1997-10-28 2003-03-27 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
WO1999029888A1 (en) 1997-12-05 1999-06-17 The Scripps Research Institute Humanization of murine antibody
US20030064397A1 (en) 1998-05-22 2003-04-03 Incyte Genomics, Inc. Transmembrane protein differentially expressed in prostate and lung tumors
US20020187472A1 (en) 2001-03-09 2002-12-12 Preeti Lal Steap-related protein
WO2001057188A2 (en) 2000-02-03 2001-08-09 Hyseq, Inc. Novel nucleic acids and polypeptides
US6949245B1 (en) 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
AU2001249411B2 (en) 2000-03-24 2007-02-15 Fahri Saatcioglu Novel prostate-specific or testis-specific nucleic acid molecules, polypeptides,and diagnostic and therapeutic methods
WO2001075177A2 (en) 2000-04-03 2001-10-11 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Tumor markers in ovarian cancer
EP2857516B1 (en) 2000-04-11 2017-06-14 Genentech, Inc. Multivalent antibodies and uses therefor
CA2420140A1 (en) 2000-08-24 2002-02-28 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
US7208157B2 (en) 2000-09-08 2007-04-24 California Institute Of Technology Proteolysis targeting chimeric pharmaceutical
JP2005504513A (ja) 2001-05-09 2005-02-17 コリクサ コーポレイション 前立腺癌の治療及び診断のための組成物及び方法
AU2002347428A1 (en) 2001-06-18 2003-01-02 Eos Biotechnology Inc. Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer
WO2003022995A2 (en) 2001-09-06 2003-03-20 Agensys, Inc. Nucleic acid and corresponding protein entitled steap-1 useful in treatment and detection of cancer
WO2003042661A2 (en) 2001-11-13 2003-05-22 Protein Design Labs, Inc. Methods of diagnosis of cancer, compositions and methods of screening for modulators of cancer
CA2476776A1 (en) 2002-02-21 2003-09-04 Duke University Reagents and treatment methods for autoimmune diseases
US9770517B2 (en) 2002-03-01 2017-09-26 Immunomedics, Inc. Anti-Trop-2 antibody-drug conjugates and uses thereof
EP2258712A3 (en) 2002-03-15 2011-05-04 Multicell Immunotherapeutics, Inc. Compositions and Methods to Initiate or Enhance Antibody and Major-histocompatibility Class I or Class II-restricted T Cell Responses by Using Immunomodulatory, Non-coding RNA Motifs
JP2005534287A (ja) 2002-04-05 2005-11-17 アジェンシス， インコーポレイテッド 癌の処置および検出において有用な９８ｐ４ｂ６との名称の核酸および対応するタンパク質
WO2003104270A2 (en) 2002-06-06 2003-12-18 Ingenium Pharmaceuticals Ag Dudulin 2 genes, expression products, non-human animal model: uses in human hematological disease
JP2004121218A (ja) 2002-08-06 2004-04-22 Jenokkusu Soyaku Kenkyusho:Kk 気管支喘息または慢性閉塞性肺疾患の検査方法
CA2495389A1 (en) 2002-08-19 2004-02-26 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
AU2002951346A0 (en) 2002-09-05 2002-09-26 Garvan Institute Of Medical Research Diagnosis of ovarian cancer
US20060183120A1 (en) 2002-10-04 2006-08-17 Teh Bin T Molecular sub-classification of kidney tumors and the discovery of new diagnostic markers
WO2004065577A2 (en) 2003-01-14 2004-08-05 Bristol-Myers Squibb Company Polynucleotides and polypeptides associated with the nf-kb pathway
KR101245983B1 (ko) 2004-03-31 2013-06-28 제넨테크, 인크. 인간화 항-ｔｇｆ-베타 항체
EP2035456A1 (en) 2006-06-22 2009-03-18 Novo Nordisk A/S Production of bispecific antibodies
WO2008027236A2 (en) 2006-08-30 2008-03-06 Genentech, Inc. Multispecific antibodies
TW200900059A (en) * 2007-02-21 2009-01-01 Medarex Inc Chemical linkers with single amino acids and conjugates thereof
SI2235064T1 (sl) 2008-01-07 2016-04-29 Amgen Inc. Metoda za izdelavo heterodimernih molekul - protitelesa fc z uporabo elektrostatičnih usmerjevalnih učinkov
RU2523419C2 (ru) 2008-07-15 2014-07-20 Дженетек, Инк. Конъюгаты производного антрациклина, способы их получения и их применение в качестве противоопухолевых соединений
MX346731B (es) 2010-04-23 2017-03-30 Genentech Inc * Producción de proteínas heteromultiméricas.
WO2013017705A1 (es) 2011-08-03 2013-02-07 Salvador Moreno Rufino Baltasar Sistema de panel para construccion con retroiluminacion a base de diodos electroluminosos
SG11201401406YA (en) 2011-10-14 2014-05-29 Spirogen Sarl Pyrrolobenzodiazepines and conjugates thereof
AU2013207900B2 (en) 2012-01-12 2017-12-07 Cambridge Enterprise Limited Compounds and methods for the enhanced degradation of targeted proteins and other polypeptides by an E3 ubiquitin ligase
WO2013106646A2 (en) 2012-01-12 2013-07-18 Yale University Compounds and methods for the inhibition of vcb e3 ubiquitin ligase
CA2872327A1 (en) 2012-05-21 2013-11-28 Genentech, Inc. Anti-ly6e antibodies and immunoconjugates and methods of use
US9492566B2 (en) 2012-12-13 2016-11-15 Immunomedics, Inc. Antibody-drug conjugates and uses thereof
US9943610B2 (en) 2012-12-21 2018-04-17 Bioalliance C.V. Hydrophilic self-immolative linkers and conjugates thereof
WO2015023355A1 (en) 2013-08-12 2015-02-19 Genentech, Inc. 1-(chloromethyl)-2,3-dihydro-1h-benzo[e]indole dimer antibody-drug conjugate compounds, and methods of use and treatment
CN105873614B (zh) 2013-12-16 2020-10-30 基因泰克公司 肽模拟化合物及其抗体-药物缀合物
NZ720743A (en) 2013-12-16 2021-12-24 Medimmune Ltd Peptidomimetic compounds and antibody-drug conjugates thereof
EP3082875B1 (en) 2013-12-16 2020-11-25 Genentech, Inc. Peptidomimetic compounds and antibody-drug conjugates thereof
KR20240038809A (ko) 2014-04-14 2024-03-25 아비나스 오퍼레이션스, 인코포레이티드 단백질분해의 이미드-기초된 조절인자 및 연관된 이용 방법
CN106573000B (zh) 2014-07-07 2020-02-07 陈昆锋 作为抗癌药物的芳基胺取代的喹喔啉
WO2016025752A1 (en) * 2014-08-14 2016-02-18 Prolynx Llc Reagents for thiol conjugation and conjugates formed therefrom
CN107001473B (zh) 2014-11-19 2021-07-09 豪夫迈·罗氏有限公司 抗-运铁蛋白受体抗体及使用方法
EP3319944A4 (en) 2015-07-10 2019-04-24 Arvinas, Inc. MDM2-BASED PROTEASE MODULATORS AND METHODS OF USE THEREOF
WO2017030814A1 (en) 2015-08-19 2017-02-23 Arvinas, Inc. Compounds and methods for the targeted degradation of bromodomain-containing proteins
CA3002709A1 (en) 2015-11-02 2017-05-11 Yale University Proteolysis targeting chimera compounds and methods of preparing and using same
CN109152843A (zh) 2016-05-20 2019-01-04 豪夫迈·罗氏有限公司 Protac抗体缀合物及其使用方法
CN108452321B (zh) * 2017-06-19 2021-11-26 四川百利药业有限责任公司 一种带酸性自稳定接头的抗体-药物偶联物
US20200038378A1 (en) 2018-04-01 2020-02-06 Arvinas Operations, Inc. Brm targeting compounds and associated methods of use
MX2020010368A (es) 2018-04-01 2021-01-08 Arvinas Operations Inc Compuestos dirigidos a brm y métodos de uso asociados.
IL282441B1 (en) 2018-10-24 2025-03-01 Hoffmann La Roche Combined chemical influencing factors of decomposition and methods of use
JP7502425B2 (ja) 2019-10-01 2024-06-18 アルヴィナス・オペレーションズ・インコーポレイテッド Ｂｒｍ標的化化合物および関連使用方法
CN115666575B (zh) 2020-04-06 2024-12-10 福宏治疗公司 化合物及其用途
KR20230042032A (ko) * 2020-07-21 2023-03-27 제넨테크, 인크. Brm 분해의 항체 접합 화학 유도제 및 이의 방법

Also Published As

Publication number Publication date
JP2025506357A (ja) 2025-03-11
CN118591393A (zh) 2024-09-03
WO2023147328A1 (en) 2023-08-03
TW202340146A (zh) 2023-10-16
US20250064968A1 (en) 2025-02-27
EP4469090A1 (en) 2024-12-04

Similar Documents

Publication Publication Date Title
AR112689A1 (es) Agonistas del receptor tipo toll 7 (tlr7) que tienen porciones aromáticas ligadas al heteroátomo, conjugados de estos y métodos y usos de estos
AR112414A1 (es) Agonistas del receptor tipo toll 7 (tlr7) que tienen una porción benzotriazol, conjugados de estos y métodos y usos de estos
CL2022003648A1 (es) Conjugados de una molécula de unión celular con análogos de camptotecina
ES2811301T3 (es) Hidrogeles reticulados por química clic y métodos de uso
Wilson et al. Stoichiometric Post‐Modification of Hydrogel Microparticles Dictates Neural Stem Cell Fate in Microporous Annealed Particle Scaffolds
EA202090410A1 (ru) АГОНИСТЫ Toll-ПОДОБНОГО РЕЦЕПТОРА 7 (TLR7), ИМЕЮЩИЕ ПИРИДИНОВЫЙ ИЛИ ПИРАЗИНОВЫЙ ФРАГМЕНТ, ИХ КОНЪЮГАТЫ, ПРИМЕНЕНИЯ И СПОСОБЫ С НИМИ
PE20161325A1 (es) L-asparaginasa tratada con peg
ES2624704T3 (es) Resinas epoxídicas con alta estabilidad térmica y tenacidad
ECSP077183A (es) Derivados de la n-(1-bencil-4-fenil-1h-imidazol-2-il)-2,2-dimetilpropil)benzamida y los compuestos relacionados como inhibidores de la proteína de quiinesina del huso (ksp) para el tratamiento del cáncer
AR069495A1 (es) Construcciones de union de antigenos para el tratamiento de cancer o enfermedades inflamatorias (asma, artritis o artrosis)
JP2006514610A (ja) フラノン誘導体およびその製造方法
Xu et al. Amide‐linkage formed between ammonia plasma treated poly (D, L‐lactide acid) scaffolds and bio‐peptides: Enhancement of cell adhesion and osteogenic differentiation in vitro
CL2021003468A1 (es) Una formulación de un conjugado de un análogo de tubulisina con una molécula de unión celular
EA201270473A1 (ru) Новые майтанзиноиды и применение упомянутых майтанзиноидов для получения конъюгатов с антителом
EA202092176A1 (ru) 177Lu-DOTA-HYNIC-iPSMA В КАЧЕСТВЕ ТЕРАПЕВТИЧЕСКОГО РАДИОФАРМАЦЕВТИЧЕСКОГО СРЕДСТВА, НАЦЕЛЕННОГО НА ПРОСТАТИЧЕСКИЙ СПЕЦИФИЧЕСКИЙ МЕМБРАННЫЙ АНТИГЕН
PE20211467A1 (es) Derivados de piridinil sulfonamida, composiciones farmaceuticas y usos de estos
AR128330A1 (es) Inductores químicos de degradación conjugados con anticuerpo y métodos de estos
AR061598A1 (es) Nitroderivados heterociclicos como antagonistas de receptor de endotelina
PE20211473A1 (es) Conjugados de anticuerpo-farmaco de herboxidieno y metodos de uso
PE20231104A1 (es) Inductores quimicos de degradacion conjugados con anticuerpo de brm y metodos de estos
MX2022002053A (es) Conjugados de il-15 y sus usos.
AR067627A1 (es) Enlazador fmoc polimerico hidrolizable. procedimiento de preparacion
MX2022000037A (es) Enlazadores hidrofilicos para conjugados de peptidos multivalentes.
PE20221006A1 (es) Compuestos antibacterianos para el tratamiento de la enfermedad de la bacteriana por "enterobacteriaceae"
EA202190298A1 (ru) Циклические динуклеотиды в качестве агонистов sting